Full Text View  
  Tabular View  
  Contacts and Locations  
  No Study Results Posted  
  Related Studies  
OPERA: French Observational Study on Patients Implanted With a Guidant PRIZM or Vitality Defibrillator
This study has been completed.
Sponsored by: Guidant Corporation
Information provided by: Guidant Corporation
ClinicalTrials.gov Identifier: NCT00180375
  Purpose

This study evaluates the date of the first appropriate and/or inappropriate therapy in patients implanted with a Guidant PRIZM or VITALITY defibrillator and is evaluating eventual predictive risk factors for appropriate/inappropriate therapies as well as the influence of the programmed parameters on these therapies.


Condition Intervention Phase
Ventricular Tachycardia
Ventricular Fibrillation
Device: Prizm, Vitality, Renewal
Phase IV

Genetics Home Reference related topics: Brugada syndrome short QT syndrome
U.S. FDA Resources
Study Type: Observational
Study Design: Prospective
Official Title: OPERA: French Observational Study on Patients Implanted With a Guidant PRIZM or Vitality Defibrillator

Further study details as provided by Guidant Corporation:

Primary Outcome Measures:
  • Time to first appropriate therapy
  • Time to first inappropriate therapy

Secondary Outcome Measures:
  • Influence of cardiopathy, EF, NYHA Class, Type of ventricular arrhythmia (MVT, PVT, VF), History of atrial and ventricular arrhythmias, medical treatment (betablockers and/or Amiodarone).
  • Type of treatment ATP/shock

Estimated Enrollment: 700
Study Start Date: May 2002
Study Completion Date: August 2007
  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Indication for an ICD according to current guidelines, incl. prophylactic indication

Exclusion Criteria:

  • pregnant or at birth bearing age without contraception, participation in another clinical trial, short life expectancy, geographically unstable for a follow-up at the investigational center
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00180375

Locations
France
CHU Pontchaillou
Rennes, France, 35033
CHU Michalon
Grenoble, France, 38043
CHU Angers
Angers, France, 49033
CHU Tours
Tours, France, 37044
CHU Montpellier
Montpellier, France, 34295
CHU Nantes
Nantes, France, 34295
CHU Rangueil
Toulouse, France, 31403
CHU Rouen
Rouen, France, 76031
CHU Clermont Ferrand
Clermont Ferrand, France, 63003
GH La Timone
Marseille, France, 13385
CH St. Joseph
Marseille, France, 13008
CH Amiens
Amiens, France, 80054
CH Besancon
Besancon, France, 25030
CHG Chateauroux
Chateauroux, France, 36019
CHU Hopital la Cavale Blanche
Brest, France, 29609
CH La Roche sur Yon
La Roche sur Yon, France, 85025
CHU Toulon
Toulon, France, 83056
CHU Dupuytren
Limoges, France, 87042
Hopital Antoine Beclere
Clamart, France, 92140
Hopital Angouleme
Angouleme, France, 16470
Hopital Nord
Marseille, France, 13915
Hopital Neuro-cardiologique
Lyon, France, 69394
Hopital Cote de Nacre
Caen, France, 14033
CHRU Robert Debré
Reims, France, 51092
CH Avignon
Avignon, France, 84902
CMC Arnaud Tzanck
St. Laurent du Var, France, 6700
CHG Aix en Provence
Aix en Provence, France, 13616
Hôpital Princesse de Grâce
Monaco, France, 98000
CHG Albi
Albi, France, 81000
CHG Pau
Pau, France, 64046
CHU Nice
Nice, France, 6002
CHG Martigues
Martigues, France, 13696
CHU D'Orleans
Orleans, France, 45000
Sponsors and Collaborators
Guidant Corporation
Investigators
Principal Investigator: Antoine LEENHARD, MD Hôpital Lariboisière, Paris
  More Information

Responsible Party: Guidant France ( Elisabeth Mouton )
Study ID Numbers: OPERA Registry, 902194
Study First Received: September 12, 2005
Last Updated: December 12, 2007
ClinicalTrials.gov Identifier: NCT00180375  
Health Authority: France: Afssaps - French Health Products Safety Agency

Study placed in the following topic categories:
Heart Diseases
Tachycardia
Paroxysmal ventricular fibrillation
Tachycardia, Ventricular
Ventricular Fibrillation
Arrhythmias, Cardiac

Additional relevant MeSH terms:
Pathologic Processes
Cardiovascular Diseases

ClinicalTrials.gov processed this record on January 16, 2009